Cancer 2 (11), 11521169
For a structured overview of the GLOW approach and how combination therapy is framed at a higher level, see: GLOW peptide overview
Disclosure of interest: Junji Fukumori: nothing to disclose, Kenji Fukutome: nothing to disclose, Shuta Aketa: nothing to disclose, Yasushi Motoyama: nothing to disclose Poster Session I - DIGITAL TRANSFORMATION, AI AND ROBOTICS 07.00 - DIGITAL TRANSFORMATION, AI AND ROBOTICS - 07.01 - TECHNOLOGY INNOVATIONS: ROBOTS, VIRTUAL REALITY, ARTIFICIAL INTELLIGENCE AND MORE P299 - ESOC25-2147 PREDICTING COGNITIVE IMPAIRMENT USING MACHINE LEARNING IN PATIENTS WITH CEREBRAL SMALL VESSEL DISEASES Tingting Mao 1 , Tingting Wang 2 , Yilong Wang 2 , Ling Guan 1,2 1 Beijing Institute of Technology, Beijing, China, 2 Beijing Tiantan Hospital, Beijing, China Background and Aims: Cerebral small vessel disease (CSVD) is a major cause of vascular cognitive impairment (VCI), yet predicting the progression of cognitive decline including different cognitive domains in patients with CSVD still remains challenge
Biomaterials 278 , 120433 (2021)
In contrast, treatment with DL-propargylglycine (PAG), a CSE inhibitor, exacerbated T2DM-induced liver injury, leading to severe hepatocellular vacuolation, heightened oxidative stress, and amplified inflammation [76]
Silky lightweight red transparent serum texture features fast-absorbing, non-sticky smooth finish
